Literature DB >> 33911819

A Case of the Safety and Efficacy of Guselkumab in Psoriasis with Alcoholic Liver Cirrhosis.

Hyun Min Nam1, Soo Hyeon Noh1, Bo Ra Lim2, Do Hyeon Kim2, Seung Yeon Lee2, Wang Guk Oh3.   

Abstract

Entities:  

Year:  2020        PMID： 33911819      PMCID： PMC7875222          DOI： 10.5021/ad.2021.33.1.88

Source DB:  PubMed          Journal:  Ann Dermatol        ISSN： 1013-9087            Impact factor:   1.444


× No keyword cloud information.
  4 in total

1.  Safety and efficacy of biological therapies in patients with psoriasis with alcoholic cirrhosis: a French retrospective study of 23 cases.

Authors:  E Begon; N Beneton; C Poiraud; C Droitcourt; C Jacobzone; A Vermersch-Langlin; V Descamps; J L Perrot; A Khemis; V Pallure; A C Fougerousse; M Sigal-Grinberg; J-L Schmutz; C Goujon; Z Reguiai
Journal:  Br J Dermatol       Date:  2018-06-21       Impact factor: 9.302

2.  Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies.

Authors:  K Reich; K A Papp; A W Armstrong; Y Wasfi; S Li; Y K Shen; B Randazzo; M Song; A B Kimball
Journal:  Br J Dermatol       Date:  2019-05       Impact factor: 9.302

3.  Safety of biologic agents for psoriasis in patients with viral hepatitis.

Authors:  Nawaf AlMutairi; Hesham Alaadin Abouzaid
Journal:  J Dermatolog Treat       Date:  2018-02-01       Impact factor: 3.359

4.  Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses.

Authors:  Lisa C Zaba; Irma Cardinale; Patricia Gilleaudeau; Mary Sullivan-Whalen; Mayte Suárez-Fariñas; Mayte Suárez Fariñas; Judilyn Fuentes-Duculan; Inna Novitskaya; Artemis Khatcherian; Mark J Bluth; Michelle A Lowes; James G Krueger
Journal:  J Exp Med       Date:  2007-11-26       Impact factor: 14.307
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.